BDX - Becton, Dickinson and Company

NYSE - NYSE Delayed Price. Currency in USD
232.89
+3.40 (+1.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close229.49
Open230.21
Bid212.01 x 100
Ask232.40 x 100
Day's Range229.34 - 233.19
52 Week Range227.72 - 234.87
Volume888,132
Avg. Volume1,014,000
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • BD Launches BD FACSymphony™ S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types
    PR Newswire23 hours ago

    BD Launches BD FACSymphony™ S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types

    New Cell Sorter Extends BD's Robust Portfolio of Flow Cytometry Research Solutions FRANKLIN LAKES, N.J. , April 26, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global ...

  • Will Boston Scientific Beat 1Q18 Earnings Estimates?
    Market Realist3 days ago

    Will Boston Scientific Beat 1Q18 Earnings Estimates?

    In 1Q18, Boston Scientific (BSX) is expected to report adjusted EPS (earnings per share) of $0.32, representing YoY (year-over-year) growth of ~8.7%. The company reported adjusted EPS of $0.34 in fiscal 4Q17, and it had registered YoY growth of ~14.8%. The adjusted EPS were in line with Wall Street expectations.

  • PR Newswire4 days ago

    BD Board Declares Dividends

    FRANKLIN LAKES, N.J. , April 23, 2018 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on June ...

  • See what the IHS Markit Score report has to say about Becton Dickinson and Co.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Becton Dickinson and Co.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • BD Unveils Suite of Diagnostic Informatics and Automation Innovations
    PR Newswire8 days ago

    BD Unveils Suite of Diagnostic Informatics and Automation Innovations

    FRANKLIN LAKES, N.J., April 19, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today introduced several new informatics and automation solutions for clinical laboratories, which may play a critical role in the fight against infectious diseases and antimicrobial resistance. The new molecular, microbiology and software solutions will be showcased at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. The company announced the plan for the commercial availability of BD Synapsys™ microbiology informatics solution, which provides laboratories with secure connectivity across instruments and locations.

  • See what the IHS Markit Score report has to say about Becton Dickinson and Co.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Becton Dickinson and Co.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BDX totaled $16.33 billion.

  • Benzinga17 days ago

    Citi Projects 16% Upside For Becton Dickinson In Upgrade

    Medical supplier Becton Dickinson and Co (NYSE: BDX ) is likely to outperform its own expectations, as well as the Street's, according to Citi. The Analyst Analyst Amit Hazan upgraded Becton Dickinson ...

  • Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?
    Market Realist22 days ago

    Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?

    Should Investors Be Interested in Varian Medical Systems? Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution. Since the launch of this radiotherapy solution in 4Q16, the company has secured 57 orders, of which 19 were placed in 1Q18.

  • See what the IHS Markit Score report has to say about Becton Dickinson and Co.
    Markit23 days ago

    See what the IHS Markit Score report has to say about Becton Dickinson and Co.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BDX totaled $17.46 billion.

  • PR Newswire24 days ago

    BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call

    FRANKLIN LAKES, N.J. , April 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2018 earnings conference ...

  • A Look at BDX’s Recent Launch and Its Applications
    Market Realist25 days ago

    A Look at BDX’s Recent Launch and Its Applications

    BDX's March 2018 Performance, Recommendations, and Updates

  • BDX Divests Its Remaining Stake in Vyaire to Apax Partners
    Market Realist28 days ago

    BDX Divests Its Remaining Stake in Vyaire to Apax Partners

    On March 19, 2018, Becton, Dickinson and Company (BDX) announced that it had entered into an agreement to divest its remaining stake in Vyaire Medical to Apax Partners for a cash payment of $435 million. Following the deal’s closure, Apax Partners will hold a 100% stake in Vyaire Medical. Vyaire Medical is a leading global respiratory care company.

  • Discussing BDX’s Recent Stock Price Performance
    Market Realist28 days ago

    Discussing BDX’s Recent Stock Price Performance

    BDX's March 2018 Performance, Recommendations, and Updates

  • Analysts’ Recommendations on BD Stock in March 2018
    Market Realist28 days ago

    Analysts’ Recommendations on BD Stock in March 2018

    BDX's March 2018 Performance, Recommendations, and UpdatesAnalysts’ latest recommendations

  • Baxter International Created a New Reporting Structure for 2018
    Market Realistlast month

    Baxter International Created a New Reporting Structure for 2018

    Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a range of one to six global businesses.

  • Baxter International’s 2018 Revenues Expected to See Modest Rise
    Market Realistlast month

    Baxter International’s 2018 Revenues Expected to See Modest Rise

    Who Is Watching Baxter International in March 2018? For fiscal 2017, Baxter International (BAX) reported revenues of ~$10.6 billion, which represents 4.0% YoY growth on a reported basis and a 5.0% rise on an operational basis. The company has projected its annual revenues for 2018 to be 6.0%–7.0% higher year-over-year (or YoY) on a reported basis.

  • Analysts’ March 2018 Ratings for Baxter International and Peers
    Market Realistlast month

    Analysts’ March 2018 Ratings for Baxter International and Peers

    Who Is Watching Baxter International in March 2018? Baxter International’s (BAX) top-line performance in 4Q17 was mainly driven by increased demand for the company’s Fluid Systems’ products. Baxter International also witnessed rising demand for its cytotoxic contract manufacturing services.

  • A Look at Medtronic’s Technical Indicators
    Market Realistlast month

    A Look at Medtronic’s Technical Indicators

    Medtronic Stock Hits 52-Week Low amid Trade War Fears

  • Trade War Fears Triggered Medtronic’s Stock Decline on March 23
    Market Realistlast month

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Medtronic Stock Hits 52-Week Low amid Trade War FearsMedtronic’s recent market performance

  • PR Newswirelast month

    BD Updates Instructions for Use for Certain BD Vacutainer® Blood Collection Tubes

    FRANKLIN LAKES, N.J., March 22, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced it is updating the instructions for use of certain BD Vacutainer® tubes as part of its quality process to ensure that customers understand the appropriate uses of these products. Since BD became aware of the concerns about inaccurate lead test results from Magellan Diagnostics LeadCare® Testing Systems, the company has been cooperating fully with the U.S. Food and Drug Administration (FDA). BD launched an internal investigation and determined that Anodic Stripping Voltammetry (ASV) technology, which is used in Magellan LeadCare testing systems, is not compatible with thiuram, a material found in the rubber stoppers of the BD Vacutainer® EDTA Lavender, Pink and Tan top tubes and BD Vacutainer® Lithium Heparin Green top tubes.

  • The Wall Street Journallast month

    [$$] Apax Buying Remaining Stake in Vyaire Medical for $435 Million

    Apax Partners acquired a majority stake in Vyaire Medical, which previously was Becton Dickinson’s respiratory services business, in October 2016, with Becton Dickinson retaining a minority stake in the ...

  • PR Newswirelast month

    BD to Divest Remaining Investment in Vyaire Medical to Funds Managed by Apax Partners

    FRANKLIN LAKES, N.J., March 19, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today that it has signed a definitive agreement to divest its remaining, minority stake in Vyaire Medical to funds managed by Apax Partners. According to the terms of the agreement, BD will receive $435 million in cash for its remaining ownership of Vyaire Medical. BD intends to use the proceeds in line with its broader capital allocation strategy.